JMJonathan Messika

Jonathan Messika

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jonathan Messika has a total of 1000 co-authors. Here are the top co-authors by number of shared publications:

  • Jean-Damien Ricard

    Université de Paris, CRI Inserm UMRS 1149, IAME Inserm UMR 1137, PHERE UMRS 1152, F-75018 Paris, France; APHP, Hôpital Louis Mourier, DMU ESPRIT, Intensive Care Unit, F-92700 Colombes, France

    11 shared publications
  • Jean-Damien Ricard

    AP-HP, Hôpital Louis Mourier, DMU ESPRIT, Service de Médecine Intensive Réanimation, Colombes, France; Université Paris Cité, UMR1137 IAME, INSERM, Paris, France

    9 shared publications
  • Antoine Roux

    11Pneumology, Adult Cystic Fibrosis Center and Lung Transplantation Department, Foch Hospital, Suresnes, France

    7 shared publications
  • Stéphane Gaudry

    Département de réanimation médico-chirurgicale, APHP Hôpital Avicenne, Bobigny, France

    7 shared publications
  • Damien Roux

    Faculté de Santé, US UPPERS, Unité de Service Pour La Pédagogie, L'Enseignement Et La Recherche, Université Paris Cité, Paris, France

    6 shared publications
  • Didier Dreyfuss

    Université de Paris, CRI Inserm UMRS 1149, IAME Inserm UMR 1137, PHERE UMRS 1152, F-75018 Paris, France; APHP, Hôpital Louis Mourier, DMU ESPRIT, Intensive Care Unit, F-92700 Colombes, France

    6 shared publications

Latest Publications

  • Open Access

    Feasibility, Safety and Outcomes of Early Mobilization in the ICU Following Lung Transplantation: A Scoping Review

    by Matthieu Reffienna, Adéla Foudhaïli, Jonathan Messika, Damien Vitiello

    Background: Lung transplantation (LTx) is performed in approximately 4500 patients worldwide each year. Postoperatively, patients are at high risk of muscle catabolism due to Intensive Care Unit (ICU)‐acquired weakness, potentially compromising functional recovery. While post‐LTx rehabilitation is usually initiated after hospital discharge, the feasibility and safety of early mobilization during the ICU stay remain unclear. This scoping review aimed to synthesize available evidence on the feasibility, safety, and outcomes of early mobilization initiated in the ICU following LTx. Methods: We conducted a scoping review with comprehensive searches in MEDLINE (via PubMed), Embase, PEDro, Web of Science, CINAHL, Scopus, Cochrane CENTRAL, and PROSPERO. Study selection, data extraction, and analysis were performed independently by two reviewers. Results: The search identified 3219 records, of which 32 sources met inclusion criteria, including 17 original studies, three conference abstracts, four registered protocols, and eight narrative reviews. Despite marked heterogeneity in study designs, interventions, and outcomes, early mobilization was consistently reported as feasible and safe, with initiation possible within the first 24 h of ICU stay. Interventions were generally multimodal, progressive, and individualized. Adverse events were infrequently reported. Conclusions: Early mobilization during the ICU stay following LTx appears feasible and safe, although the evidence is limited by the small number of studies and the predominance of low‐level designs. Based on the available literature, we propose a preliminary mobilization framework tailored to this population. Further high‐quality studies are required to confirm these findings and to evaluate clinical benefits. Trial Registration: Open Science Framework https://osf.io/nhr3e


  • Escherichia coli, de la colonisation oropharyngée à l'infection pulmonaire : épidémiologie et physiopathologie

    by Jonathan Messika

    La pneumonie acquise sous ventilation mécanique (PAVM) est la complication infectieuse principale des patients de réanimation. Le carrefour oropharyngé et sa colonisation semblent être l’une des clés de sa physiopathologie, et est la cible de leur prévention. Parmi les agents étiologiques des PAVM, Escherichia coli en est un prédominant. Cependant, le manque de données concernant son implication dans la colonisation oropharyngée, et dans les PAVM est criant. Cette thèse a pour objectif un abord multi-facettes de la PAVM à E. coli. Il s’agit d’abord d’actualiser les données épidémiologiques des PAVM, en plaçant les entérobactéries en général, et E. coli en particulier comme agent d’importance ; puis de décrire les caractéristiques génotypiques et phénotypiques des isolats d’E. coli responsables de colonisation ou d’infection respiratoire ; ensuite d’étudier la colonisation à bacilles à Gram négatif pathogènes dans différentes populations de gravités différentes ; et enfin de décrire les caractéristiques des isolats d’E. coli oropharyngés dans ces populations et de les comparer aux isolats rectaux concomitants.Ainsi, dans notre premier travail, nous confirmons l’importance des entérobactéries comme agents pathogènes de premier plan au cours des PAVM. Au sein des entérobactéries, nous mettons en évidence la place centrale d’E. coli en particulier en matière de résistance aux antibiotiques. La prédominance respiratoire des isolats d’E. coli de phylogroupe B2 a été confirmée dans un travail monocentrique mené dans notre service, et dans une cohorte nationale de patients de réanimation. De plus, le groupe B2 prédominait aussi au sein des prélèvements rectaux et oropharyngés. Nous avons confirmé la virulence extra-digestive des isolats en corrélant le contenu en facteur de virulence et la mortalité dans un modèle murin de pneumonie. Enfin, une large étude épidémiologique de la colonisation oropharyngée en général, et des caractéristiques d’isolats d’E. coli la composant en particulier, chez des patients de gravités différentes et chez des sujets sains est en cours.L’ensemble de ces données permettra une plus grande compréhension de la physiopathologie de survenue des PAVM, une meilleure connaissance de la population d’E. coli colonisant l’oropharynx et causant les PAVM. Ainsi, des mesures préventives ciblées pourraient être développées.

  • Open Access

    Female pulmonologists experienced poorer health and reduced quality of life related to their professional activities

    by Claire Leloup, Emilie Mesa, Damien Basille, Augustin Boudoussier, Arnaud Maurac, Léo Grassion, Camille Rolland-Debord, Iban Larrouture, Clémence Martin, Florence Jeny, et al.

    Background: Despite increasing gender parity in medical school enrolment, disparities in career progression and physician well-being persist. This study evaluated professional experiences, health status and perceived gender-related barriers among pulmonologists in France. Methods: A nationwide, anonymous cross-sectional survey (546-item) was distributed to all French pulmonologists between July 2023 and February 2024. Data included work-related health disorders, career paths and gender perceptions. Gender differences in dissatisfaction and health issues were assessed (chi 2 and Fisher's exact tests). Multivariate logistic regression models were used to evaluate the impact of gender on career outcomes. Results: A total of 586 pulmonologists responded (21% response rate), 57% of whom were women; median age of 38 (interquartile range 32–49) years. Job satisfaction was moderate (mean± sd score of 3.5±1.0, out of 5)). Mental health issues were common. 51.5% reported anxiety, 22.0% burnout, 16.9% depression and over 60% had sleep disturbances. Women reported significantly higher rates of anxiety (58.8% versus 44.2%), burnout (27.9% versus 15.4%) and anxiolytic use (23.0% versus 14.5%) than men. Gender was a limiting factor in career choices (OR 1.99, 95% CI 1.41–2.80) and opportunities (OR 2.22, 95% CI 1.57–3.15), particularly among female physicians with children. Women were more likely than men to adjust their career plans for family reasons (18% versus 12%) or job offers (67.0% versus 33.1%). In multivariate analyses, gender remained a limiting factor in career choices (OR 2.00, 95% CI 1.39–2.90) and opportunities (OR 2.39, 95%CI 1.65–3.48), after adjustment for age, number of children and practice settings. Conclusion: This national survey highlights notable gender-based disparities in mental health and career advancement among French pulmonologists.

  • Open Access

    Refractory antibody-mediated rejection after high-emergency lung transplantation for dermatomyositis with anti-MDA5 antibody: a case report

    by Louise Chantelot, Domitille Mouren, Jean-Luc Taupin, Aurélie Cazes, Jonathan Messika, Cendrine Godet, Mathilde Salpin, Gaelle Weisenburger, Brice Lortat-Jacob, Pierre Mordant, et al.

    Louise Chantelot, Domitille Mouren, Jean-Luc Taupin, Aurélie Cazes, Jonathan Messika, Cendrine Godet, Mathilde Salpin, Gaelle Weisenburger, Brice Lortat-Jacob, Pierre Mordant, Jean-François Alexandra, Raphael Borie, Chloé Comarmond, Yves Allenbach, Yurdagül Uzunhan, Hervé Mal, Antoine Roux, Vincent Bunel. Clin Transplant Res -0001;0:. https://doi.org/10.4285/ctr.25.0034

  • Infections pulmonaires en soins critiques chez les patients transplantés pulmonaires

    by Marc Doman, Alexy Tran-Dinh, Jonathan Messika

    L’infection respiratoire sévère est la cause principale de dysfonction aigue d’allogreffe pulmonaire, et un motif d’admission en réanimation important des patients ayant eu une transplantation pulmonaire (TP). Cette revue aborde l’épidémiologie descriptive des infections pulmonaires en soins critiques des patients TP, en particulier au regard des données disponibles de la littérature. Les infections pulmonaires regroupent pneumonies et trachéobronchites, de pronostic différent à court ou long terme. L’épidémiologie microbienne dépend du délai de la greffe, des colonisations préalables du patient. Les virus respiratoires communautaires sont rarement pourvoyeurs d’admission en soins critiques. La démarche diagnostique d’une dysfonction aigue d’allogreffe pulmonaire avec insuffisance respiratoire aiguë doit faire évoquer en premier lieu une infection pulmonaire, mais la présence d’un agent infectieux dans un prélèvement respiratoire ne doit pas faire écarter le diagnostic d’une atteinte spécifique. Les analyses cliniques et scannographiques guideront le traitement initial, et les investigations microbiologiques. Les données de l’endoscopie bronchique permettront d’éliminer certains diagnostics différentiels.

  • Trajectories of FEV1 after lung transplantation and patient outcomes

    by Marc Raynaud, Natalia Belousova, Matthieu Glorion, Caroline Hillebrand, Clément Picard, Zehra Nizar Dhanani, Laurence Beaumont-Azuar, Sylvie Colin de Verdière, Édouard Sage, Jonathan Messika, et al.


  • Baseline Allograft Dysfunction in Single-lung Transplant Recipients: More Questions Than Answers?

    by Marie Spaes, Clément Picard, Natalia Belousova, Jonathan Messika

  • Open Access

    Early mobilization after lung transplantation: A scoping review protocol

    by Matthieu Reffienna, Adéla Foudhaïli, Colin Sidre, Damien Vitiello, Jonathan Messika


  • Open Access

    Is MUC5B rs35705950 promoter polymorphism associated with chronic lung allograft dysfunction?

    by Adèle Sandot, Ibrahima Ba, Clément R. Massonnaud, Raphaël Borie, Benjamin Renaud-Picard, Benjamin Coiffard, Xavier Demant, Loïc Falque, Antoine Roux, Jérôme Le Pavec, et al.

    Background: Chronic lung allograft dysfunction (CLAD) is the main cause of death following lung transplantation (LT). Its pathophysiology and risk factors remain poorly understood. Donor or recipient genetic characteristics could be involved. MUC5B promoter rs35705950 polymorphism is one of the major genetic factors associated with pulmonary fibrosis. We aimed to correlate the MUC5B genotype of recipients and donors with LT outcomes. Methods: Recipient and donor blood samples from the Cohort in Lung Transplantation biobank were used. MUC5B status was determined by quantitative PCR using probes for rs35705950 polymorphism. CLAD occurrence and phenotype were blindly adjudicated. Results: 210 recipient–donor pairs were analysed. At 5 years, 68 patients (32.4%) had CLAD. The MUC5B rs35705950 polymorphism, whether in the donor or the recipient, was not associated with CLAD at 5 years (OR 1.07 (95% CI 0.53–2.11), p=0.8, and OR 0.79 (95% CI 0.37–1.60), p=0.5, respectively), CLAD-free survival or CLAD phenotype. The prevalence of the recipients’ T allele differed among underlying respiratory diseases (20.0% in interstitial lung disease, 8.4% in emphysema, 13.4% in cystic fibrosis and 5.6% for others, p=0.03). Risk of antibody-mediated rejection (AMR) was independent of the donor MUC5B polymorphism genotype, whereas the presence of the T allele in the recipient was associated with a reduced occurrence of AMR (OR 0.26 (95% CI 0.08–0.69), p=0.015). Conclusion: MUC5B rs35705950 polymorphism in the donor or the recipient does not affect LT outcomes. The significant association between the recipients’ polymorphism and reduced AMR occurrence has yet to be confirmed.


  • Open Access

    Antibody-Mediated Rejection in Lung Transplantation: Diagnosis and Therapeutic Armamentarium in a 21st Century Perspective

    by Jonathan Messika, Natalia Belousova, François Parquin, Antoine Roux

    Humoral immunity is a major waypoint towards chronic allograft dysfunction in lung transplantation (LT) recipients. Though allo-immunization and antibody-mediated rejection (AMR) are well-known entities, some diagnostic gaps need to be addressed. Morphological analysis could be enhanced by digital pathology and artificial intelligence-based companion tools. Graft transcriptomics can help to identify graft failure phenotypes or endotypes. Donor-derived cell free DNA is being evaluated for graft-loss risk stratification and tailored surveillance. Preventative therapies should be tailored according to risk. The donor pool can be enlarged for candidates with HLA sensitization, with strategies combining plasma exchange, intravenous immunoglobulin and immune cell depletion, or with emerging or innovative therapies such as imlifidase or immunoadsorption. In cases of insufficient pre-transplant desensitization, the effects of antibodies on the allograft can be prevented by targeting the complement cascade, although evidence for this strategy in LT is limited. In LT recipients with a humoral response, strategies are combined, including depletion of immune cells (plasmapheresis or immunoadsorption), inhibition of immune pathways, or modulation of the inflammatory cascade, which can be achieved with photopheresis. Altogether, these innovative techniques offer promising perspectives for LT recipients and shape the 21st century’s armamentarium against AMR.